| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.069 | 0.1 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.089 | 0.1 |